Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer

Volume: 34, Issue: 12, Pages: 2579 - 2595
Published: Sep 18, 2017
Abstract
Antibody-drug conjugates (ADCs) are ushering in the next era of targeted therapy against cancer. An ADC for cancer therapy consists of a potent cytotoxic payload that is attached to a tumour-targeted antibody by a chemical linker, usually with an average drug-to-antibody ratio (DAR) of 3.5-4. The theory is to deliver potent cytotoxic payloads directly to tumour cells while sparing healthy cells. However, practical application has proven to be...
Paper Details
Title
Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
Published Date
Sep 18, 2017
Volume
34
Issue
12
Pages
2579 - 2595
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.